Biopsy assessment of drug efficacy in the gastrointestinal tract.
When using biopsy pathology in clinical pharmacology to assess drug efficacy in the gastrointestinal tract, a number of questions must be answered: Is the biopsy necessary or more effective than macroscopic views by endoscopy? Can we extract maximal information from the specimen? Are there surrogate serum or other markers that give an overall measure of disease and/or improvement? Indeed, clinicopathological correlation is of paramount importance. If biopsy is to be used, it is important to utilize appropriate scoring systems. Many grading systems use continuous spectra, which are ordinal categorical variables and therefore a grading system of assigned 'numbers' which cannot be used in processes that require continuous variables such as linear regression. The use of grading vs a 'true' score with real numbers must be carefully considered, the site and number of biopsies must be precisely chosen and interobserver reproducibility of results evaluated before undertaking drug trials. Immunocytochemistry and in situ hybridization, however, can provide quantifiable molecular information related to mechanisms of drug action. The biopsy is of significant value as it is a true in vivo assessment if the above caveats are taken into account. However, further work is needed to determine sound histological criteria to assess the efficacy of drugs for use in gastrointestinal disease.
Walker
Marjorie M
MM
Department of Histopathology, Division of Investigative Science, Faculty of Medicine, Imperial College London, Norfolk Place, London W2 1PG. mm.walker@imperial.ac.uk
D001706:Biopsy / Q000379:methods*; D004064:Digestive System / Q000473:pathology*; D005767:Gastrointestinal Diseases / Q000469:parasitology*; D006801:Humans